Research programme: protein drug interaction based therapeutics - Gandeeva Therapeutics
Latest Information Update: 04 Apr 2023
At a glance
- Originator Gandeeva Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 30 Mar 2023 Gandeeva Therapeutics and Moderna Therapeutics entered into a research collaboration agreement to explore applications of its cryo-EM technology platform
- 02 Feb 2022 Protein drug interaction based therapeutics is available for licensing as of 02 Feb 2022. https://www.gandeeva.com/
- 02 Feb 2022 Early research in Unspecified in Canada (unspecified route)